Cradle
Machine learning platform for protein lead optimization in drug design
cradle.bio ↗📍 Amsterdam, Netherlands and Zurich, Switzerland
Verified Data
“$103M total; Series B ($73M)”
Company Profile
Contact
@cradlebioStrategic Analysis
Strategy
Enterprise SaaS targeting large pharmaceutical and biotech companies with AI-powered protein design platform. Land-and-expand model serving 6 of top 25 pharma companies. Betting on machine learning to accelerate drug discovery and protein optimization workflows.
Tactics
Partnership-driven growth through integrations with platforms like Ginkgo Bioworks. Technical validation via whitepapers demonstrating 12x performance improvements. Direct enterprise sales with custom pricing for large pharma accounts.
Competitive Positioning
Differentiates on speed and automation - delivering 2x to 12x faster protein candidate production versus traditional methods. Positions as the AI-native solution for protein engineering versus legacy computational biology tools.
Marketing Approach
Technical content marketing through whitepapers and case studies. Partnership announcements and integration showcases. Direct enterprise outreach to biotech research teams at pharmaceutical companies.
Notable
Serves 6 of the top 25 pharmaceutical companies, partnership with Ginkgo Bioworks
🔗 Source ↗Tech Stack
Google Cloud Platform
Python
TypeScript
React
PyTorch
TensorFlow
Docker
KubernetesRecent News
Related AI Healthcare Companies
Discovery Sources
Signals
“$103M total; Series B ($73M)”
Evidence
Lead optimisation is the step in drug design where you take a molecule that sort of works and try to make it actually work.
~$5M+ ARR
6 of the top 25 pharmaceutical companies
100-150 employees
2x to 12x faster protein candidate production
50K-100K monthly visits